Hikma sees pandemic-driven demand spike
The firm is to pay the final dividend and reiterated previous guidance for the full year
Company
Hikma Pharmaceuticals PLC
OTCMKTS: HKMPF
Hikma Pharmaceuticals PLC is a pharmaceutical company engaged the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
45 stories · page 3 of 3
Hikma Pharmaceuticals upgraded to ‘overweight’ by JP Morgan after Vascepa litigation win
A US court this week ruled in favour of Hikma, which is developing a generic version of Amarin's Vascepa
Hikma wins litigation over heart disease prevention drug
The pharma company is developing a generic version of Vascepa, commercialised by Amarin
Hikma in nasal spray licence agreement, full-year profits soar
The firm said it is not experiencing disruption from the coronavirus outbreak while profits soared in 2019
Hikma hurt by JP Morgan downgrade to ‘underweight’
Analysts at the investment bank said headwinds at the generics division are “underappreciated”